Drug intelligence / Profile preview

ATG-012

Development stage: Discontinued
Lead developer: Antengene
Modality: Small Molecules

Overview

**ATG-012** is a small molecule inhibitor targeting the KRAS G12C mutation, developed by Antengene Corporation for oncology applications. It inhibits the activity of mutant KRAS G12C protein, a key oncogene driving tumor growth in various solid tumors. Preclinical studies demonstrate tumor growth inhibition as monotherapy and strong synergism in combinations with ERK1/2 inhibitors like ATG-017, SHP2 inhibitors, and PD-L1/4-1BB bispecific antibodies like ATG-101, positioning it as a potential combination agent.[1][3][4][5]

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on ATG-012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATG-012.

Explore the full profile